The VJSessions | VJHemOnc

Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The VJSessions have brought together leading experts virtually to help continue the valuable international collaborations in diseases such as Multiple Myeloma, CLL, AML, Lymphoma, MDS and MPNs. You can view our collection of webinar sessions below at your convenience, as well as being able to listen to podcasts of each session on the go.

Multiple Myeloma

Multiple Myeloma

Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting

Peter Voorhees, Holly Lee

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more

Kenneth Anderson, Francesco Maura, Mehmet Samur

Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more

Ajai Chari, Nisha Joseph, Ross Firestone

Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level

Gareth Morgan, Paola Neri

Important considerations for community oncologists regarding the use of T-cell therapies in myeloma

Rachid Baz, Damian Green

Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics

Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more

Rafael Fonseca, Ola Landgren, Thomas Martin, Adriana Rossi

Genomics & epigenomics in multiple myeloma: key updates and potential clinical applications

Gareth Morgan, Lawrence Boise, Benjamin Barwick

Evaluating mechanisms of resistance to myeloma therapies & implications for clinical practice

Leif Bergsagel, Charlotte Pawlyn

Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more

Yi Lin, Rakesh Popat, Sham Mailankody, Doris Hansen

Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more

Saar Gill, Francesco Maura, Maik Luu, Ciara Freeman

MRD as an early endpoint for accelerated approval in myeloma: current perspectives & future outlooks

Ola Landgren, Dickran Kazandjian

Clinician & patient perspectives on the value of MRD in myeloma: what should patients know?

Joseph Mikhael, Jenny Ahlstrom

Ongoing research at the MMRF: Horizon Clinical Trials Program

Hearn Jay Cho, Sham Mailankody, George Mulligan, Cindy Varga

Novel technologies being explored for MRD detection in myeloma: CTCs, NGS & more

Hans Lee, David Coffey, Benjamin Diamond

iwGPRC5D 2025: highlights from the workshop

Saad Usmani, Sham Mailankody

Immune profiling of BM microenvironment to identify predictors of disease progression in myeloma

George Mulligan, Chaitanya Acharya

Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor

George Mulligan, Chaitanya Acharya

Roundtable Discussions from IBC 2024

Irene Ghobrial, Kwee Yong, Omar Nadeem, Francesco Maura, Elizabeth O'Donnell, Shaji Kumar, Elena Zamagni, Bruno Paiva, Urvi Shah

Session highlights and overview: exploring the cellular origins of multiple myeloma

Leif Bergsagel, Marta Chesi

Key highlights from EHA 2023

Jesús San Miguel, Enrique Ocio

iwMyeloma 2023

Leif Bergsagel, Francesco Maura, Jill Corre, Niels Weinhold, Irene Ghobrial, Charlotte Pawlyn, Lawrence Boise, Paola Neri, Maria Victoria-Mateos, Marta Chesi, José Ángel Martínez-Climent, Bruno Paiva, Keith Stewart, Brian Walker, Martin Kortüm, Claudia Stege, Elena Zamagni, Enrique Ocio, Nizar Bahlis, Carlos Fernández De Larrea, Gareth Morgan, Pieter Sonneveld, Sagar Lonial, Yi Lin, Adam Cohen

Identification of a T-cell population associated with outcomes in myeloma with t(4;14) translocation

Andreas Schmidt, Jonathan Scolnick

Key highlights from ASH 2022

Yi Lin, Krina Patel

Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks

Yi Lin, Krina Patel

Updates from IMS 2022

Rakesh Popat, Charlotte Pawlyn, Meral Beksac, Heinz Ludwig, Marta Chesi, Leif Bergsagel, Sonja Zweegman, Claudia Stege, Ola Landgren, Bruno Paiva

Myeloma updates from EHA 2022

Mohamad Mohty, Saad Usmani

Myeloma treatment in the UK

Martin Kaiser, Graham Jackson

Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma

Yi Lin, Suzanne Trudel, Frederick Locke, Krina Patel

iwCAR-T 2022 day 3 highlights with a focus on myeloma

Krina Patel, Suzanne Trudel, Yi Lin, Frederick Locke

PIKfyve, RAS, the epigenome & PROTAC therapy

Paola Neri, Lawrence Boise

Day 2 wrap-up: pushing myeloma boundaries

Rafael Fonseca, Gareth Morgan, Keith Stewart, Leif Bergsagel

T-Cell Engagers: targets, challenges and opportunity

Thomas Martin, Hermann Einsele, Nina Shah

Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy

Lawrence Boise, Paola Neri

Day 1 highlights from Myeloma 2022

Keith Stewart, Gareth Morgan, Faith Davies

Day 2 highlights from Myeloma 2022

Gareth Morgan, Rafael Fonseca, Leif Bergsagel, Keith Stewart

T-Cell engagers

Hermann Einsele, Nina Shah, Thomas Martin

Novel targets in 2022

Faith Davies, Charlotte Pawlyn, Hearn Jay Cho

Using single-cell analysis to tackle myeloma

Irene Ghobrial, Yael Cohen, Eileen Boyle, Rodger Tiedemann

Genomics in the age of I-O

Gareth Morgan, Francesco Maura, Leo Rasche

Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics

Faith Davies, Gareth Morgan, Keith Stewart

Novel targets in 2022

Faith Davies, Hearn Jay Cho, Charlotte Pawlyn

Genomics in the age of I-O

Gareth Morgan, Francesco Maura, Leo Rasche

Using single-cell analysis to tackle myeloma

Irene Ghobrial, Rodger Tiedemann, Eileen Boyle, Yael Cohen

Post-ASH 2021

Graham Jackson, Rakesh Popat

A deep dive into screening for precursor conditions

Irene Ghobrial, Sigurdur Kristinsson

Screening for myeloma precursors: iStopMM, PROMISE, and the questions they have raised

Irene Ghobrial, Sigurdur Kristinsson

Next steps for myeloma research and treatment

Faith Davies, Gareth Morgan

Patient segmentation for targeted therapy in myeloma

Faith Davies, Gareth Morgan

Women in myeloma

Irene Ghobrial, Maria Victoria-Mateos

The new era of myeloma therapies

Irene Ghobrial, Maria Victoria-Mateos

Screening programs for plasma cell disorders

Irene Ghobrial, Maria Victoria-Mateos

Precursor conditions: management of smoldering myeloma

Irene Ghobrial, Maria Victoria-Mateos

Patient empowerment in myeloma

Heinz Ludwig, Hermann Einsele

IMW 2021 award winners

Heinz Ludwig, Hermann Einsele

MRD in myeloma: the FDA perspective

Heinz Ludwig, Hermann Einsele

Long-term disease-free survival in myeloma

Heinz Ludwig, Hermann Einsele

Key highlights of IMW 2021

Heinz Ludwig, Hermann Einsele

The IMW 2021 congress and COVID-19

Heinz Ludwig, Hermann Einsele

Post-EHA/ASCO 2021

Noopur Raje, Katja Weisel, Nina Shah, Yi Lin

The patient perspective

Mohamad Mohty, , , ,

Post-COMy 2021

Mohamad Mohty, Thierry Facon, Alessandra Larocca

Post-ASH 2020

Maria Victoria-Mateos, Nina Shah, Thomas Martin

Post-ASH 2020 UK

Karthik Ramasamy, Rakesh Popat

Myeloma & COVID-19

Paul Richardson, Evangelos Terpos, Maria Victoria-Mateos, Ajai Chari

COMy & EHA 2020

Francesca Gay, Saad Usmani, Mohamad Mohty

CAR T-cell therapy in myeloma

Edward Stadtmauer, Yi Lin, Krina Patel

Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

John Gribben, David Maloney, Saar Gill

An MRD discussion: when, who and how

Faith Davies, Maria Victoria-Mateos, Nikhil Munshi

Advances in the clinical management of SM

Shaji Kumar, Faith Davies, Maria Victoria-Mateos

PROMISE: why early detection of MGUS is vital to reducing MM incidence

Irene Ghobrial, Kenneth Anderson, Robert Kyle

How will novel agents affect the amyloidosis population?

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo

The evolving myeloma diagnosis criteria

Shaji Kumar, Faith Davies, Maria Victoria-Mateos

MRD as a surrogate endpoint: what remains for FDA approval?

Faith Davies, Maria Victoria-Mateos, Nikhil Munshi

Translating myeloma genomics into treatment strategies

Gareth Morgan, Marc Raab

MRD evaluation: a key component of MM management?

Mohamad Mohty, Elena Zamagni, Joaquin Martinez-Lopez

CAR-T: hurdles and ladders

Faith Davies, Noopur Raje, David Avigan, Adam Cohen

Transplantation in modern myeloma therapeutics

Mohamad Mohty, Andrew Spencer, Philip McCarthy, David Siegel

Does maintenance therapy increase overall survival in myeloma?

Mohamad Mohty, Andrew Spencer, Philip McCarthy, David Siegel

Targeted therapy in MM

Rafael Fonseca, Enrique Ocio, Sagar Lonial

Immunotherapy in myeloma: current strategies and future perspectives

Niels van de Donk, Saad Usmani, Ajai Chari

Genomics and proteomics of drug resistance in myeloma: PIs, IMiDs & CD38

Sagar Lonial, Brian Van Ness, Florian Bassermann, Anja Seckinger

Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance

Keith Stewart, Thomas Martin, Florian Bassermann

Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets

Keith Stewart, Sagar Lonial, Kenneth Anderson

CAR T-cells in myeloma: exploratory targets & payment models

Andrew Spencer, Ravi Vij, David Siegel

Where in the treatment sequence should CAR T-cells be used for myeloma?

Andrew Spencer, Ravi Vij, David Siegel

Progression and treatment of MGUS-SMM-MM & epigenetics

Suzanne Lentzsch, Lawrence Boise, Elisabet Manasanch

Is precision medicine a bust in myeloma?

Rafael Fonseca, Faith Davies, Dirk Hose, Jeffrey Wolf

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Gareth Morgan, Keith Stewart, Leif Bergsagel

Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances

Gareth Morgan, Leif Bergsagel, Nina Shah

Debate on the use of MRD for multiple myeloma management

Bruno Paiva, Nina Shah, Jeffrey Wolf, Roger Owen, Joaquin Martinez-Lopez

Optimism for the use of liquid biopsies in multiple myeloma

Irene Ghobrial, Andrew Spencer, Marc Raab, Niels Weinhold, Rodger Tiedemann

Re-evaluating the role of epigenetics in multiple myeloma

Brian Walker, Suzanne Lentzsch, Wee Joo Chng

Multiple myeloma: consensuses and controversies

Faith Davies, Jonathan Kaufman, Peter Voorhees

Multiple myeloma: genomic evolution

Marc Raab, Jonathan Keats

The exciting field of imaging in multiple myeloma

Jens Hillengass, Saad Usmani

The use of CAR T-cells in multiple myeloma

Yi Lin, Adam Cohen, Sabrina Prommersberger

Novel therapeutics in multiple myeloma

Constantine Mitsiades, Lawrence Boise, Thomas Martin, Christoph Driessen

The future of immunotherapy in multiple myeloma

Hearn Jay Cho, Tuna Mutis, Ivan Borrello

Why use model systems for multiple myeloma research?

Enrique Ocio, Lawrence Boise, Marta Chesi, Kenneth Shain

Exciting new developments in multiple myeloma

Irene Ghobrial, Lawrence Boise, Daniel Auclair, Nina Shah, Jonathan Keats

COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards

Mohamad Mohty, Arnon Nagler

COMy 2017: Day 1 discussion on progress in multiple myeloma, patient advocacy and drug costs

Mohamad Mohty, Arnon Nagler

Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma

Irene Ghobrial, Bruno Paiva, Hervé Avet-Loiseau

Working towards a cure for multiple myeloma

Brian Walker, Irene Ghobrial, Jesús San Miguel, Hervé Avet-Loiseau

New tools for multiple myeloma treatment monitoring

Bruno Paiva, Jesús San Miguel, Hervé Avet-Loiseau, Michele Cavo

Frontline treatment for young multiple myeloma patients

Joan Bladé, Philippe Moreau, Gareth Morgan

An update on immunotherapy for multiple myeloma in 2016

Jesús San Miguel, Paula Rodríguez-Otero, Ignacio Bermejo

Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory

Joan Bladé, Jesús San Miguel, Enrique Ocio, Thierry Facon

Are we ready for mutational directed treatment: addressing the genomic basis of myeloma

Gareth Morgan, Hervé Avet-Loiseau

COMy 2016: Highlights from Day 1

Mohamad Mohty, Arnon Nagler

A multiple myeloma patient story - a discussion between Vivien de Gunzburg and Paul Richardson

Paul Richardson, Vivien de Gunzburg

How to address the issue of access to new drugs in multiple myeloma

Paul Richardson, Vivien de Gunzburg

Highlights from COMy and how to reset the immune system in multiple myeloma

Paul Richardson, Vivien de Gunzburg

The importance of multiple myeloma foundations and a patient story

Paul Richardson, Vivien de Gunzburg

COMy 2016: Highlights from Day 2

Mohamad Mohty, Arnon Nagler

Myeloma 2016: Panel discussion on the environment biology of myeloma

Stephen Russell, Dirk Hose, Suzanne Lentzsch

Myeloma 2016: Panel discussion on gene modified T-cells

James Kochenderfer, Edward Stadtmauer, Michael Hudecek, Ivan Borrello

MMRF presents highlights for patients at Myeloma 2016

Keith Stewart, Sagar Lonial, Daniel Auclair, Kenneth Anderson

Myeloma 2016: Panel discussion on novel treatments

Keith Stewart, Sagar Lonial, Leif Bergsagel, Kenneth Anderson

ASH 2014: Ask the experts Q&A session 1

Stephan Grupp, Catherine Bollard, Philippe Armand, Craig Moskowitz, Nicola Gökbuget

Triple combination therapies for multiple myeloma (MM) patients

Heinz Ludwig, Niels van de Donk

Myeloma 2016: Panel discussion on in vivo drug screening

Noopur Raje, Caroline Heckman, Constantine Mitsiades

Myeloma 2016: Panel discussion on the status of genomics

Gareth Morgan, Michele Cavo, Wee Joo Chng

Myeloma 2016: Panel discussion on the application of genomics studies

Pieter Sonneveld, Leif Bergsagel, Raymond Comenzo

Myeloma 2016: Panel discussion on the new treatment paradigm

Gareth Morgan, Jesús San Miguel, Keith Stewart, Kenneth Anderson

How can novel targets be incorporated into MM treatment?

Faith Davies, Keith Stewart, Leif Bergsagel, Robert Orlowski

The role of the microenvironment in multiple myeloma

Bruno Paiva, Marta Chesi, Ivan Borrello

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs

James Kochenderfer, Adam Cohen, Andrzej Jakubowiak

MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing

Ola Landgren, Gareth Morgan, Jens Lohr, Angela Dispenzieri

Is MRD testing ready for prime time in myeloma?

Ola Landgren, Gareth Morgan, Jens Lohr, Angela Dispenzieri

The definitive guide to multiple myeloma at ASH 2018: part I

Mohamad Mohty, Saad Usmani

The definitive guide to multiple myeloma at ASH 2018: part II

Mohamad Mohty, Saad Usmani

The definitive guide to multiple myeloma at ASH 2018: part III

Mohamad Mohty, Saad Usmani

The definitive guide to multiple myeloma at ASH 2018: part IV

Mohamad Mohty, Saad Usmani

The definitive guide to multiple myeloma at ASH 2018: part V

Mohamad Mohty, Saad Usmani

Highlights from IMW 2019 Part I

Katja Weisel, Francesca Gay

Updates in multiple myeloma

Rafael Fonseca, Yi Lin, Nizar Bahlis, Sham Mailankody

Updates in the genomics of SMM & multiple myeloma

Leif Bergsagel, Niels Weinhold, Francesco Maura, Jill Corre

Resistance mechanisms mediated by the microenvironment in multiple myeloma

Irene Ghobrial, Lawrence Boise, Charlotte Pawlyn, Paola Neri

Using animal models & the microenvironment to better understand the biology of multiple myeloma

Bruno Paiva, Maria Victoria-Mateos, Marta Chesi, Jose Martinez-Climent

The future of myeloma therapy

Brian Walker, Keith Stewart, Martin Kortüm, Claudia Stege

Novel therapeutic strategies in multiple myeloma

Enrique Ocio, Carlos Fernández De Larrea, Elena Zamagni, Nizar Bahlis

Reaching a cure for multiple myeloma

Gareth Morgan, Sagar Lonial, Pieter Sonneveld

Key myeloma highlights from EHA 2023

Jesús San Miguel, Enrique Ocio

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics

Francesco Maura, Elizabeth O'Donnell

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques

Shaji Kumar, Bruno Paiva, Elena Zamagni

Early interception in SMM & novel agents being explored

Irene Ghobrial, Kwee Yong, Omar Nadeem

The value of genomics in multiple myeloma & applying this in clinical practice

Gareth Morgan, Arun Wiita, Francesco Maura, Sarah Gooding

Understanding mechanisms of resistance to targeted therapies in myeloma

Leif Bergsagel, Charlotte Pawlyn, Paola Neri, Francesco Maura

Improving our understanding of myeloma biology: mouse models, epigenetics & spatial transcriptomics

Robert Orlowski, Niels Weinhold, Felipe Prósper

Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more

Ola Landgren, Suzanne Lentzsch, Thomas Martin, Suzanne Trudel

Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities

Faith Davies, Gareth Morgan, Louis Williams

Novel targets & agents in myeloma

Faith Davies, Mala Shanmugam, Sikander Ailawadhi

History and upcoming projects of the MMRF

Lawrence Boise, Hearn Jay Cho

CTCs in HRMM: their value in diagnosis, prognosis, and guiding treatment decisions

Irene Ghobrial, Gareth Morgan, Juan José Garcés

Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies

Niels van de Donk, Thomas Martin, Saad Usmani, Ajai Chari

CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs

Ajai Chari, Krina Patel

Defining high-risk multiple myeloma: recent advances in the field & future considerations

Kenneth Anderson, Francesco Maura, Simon Harrison

Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more

Faith Davies, Mehmet Samur

An insight into designing randomized studies in high-risk myeloma

Francesca Gay, Sham Mailankody, Binod Dhakal

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population

Heinz Ludwig, Meral Beksac

Management of high-risk and frail patients, MRD & teclistamab

Rakesh Popat, Charlotte Pawlyn

Optimal management of intermediate-fit and frail elderly patients with myeloma & refining frailty

Sonja Zweegman, Claudia Stege

The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies

Leif Bergsagel, Marta Chesi

Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies

Mohamad Mohty, Saad Usmani

Myeloma treatment updates: a UK perspective

Martin Kaiser, Graham Jackson

Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials

Meghan Thompson, Alexey Danilov

Identifying and targeting survival co-dependencies of CLL resistant to venetoclax

Deepa Sampath, Daisy Diaz Rohena

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease

Arnon Kater, Paolo Ghia

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

David Maloney, Mazyar Shadman, Alexey Danilov

Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy

Paolo Ghia, Arnon Kater

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment

Barbara Eichhorst, Lydia Scarfò, Anna Schuh

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment

Barbara Eichhorst, Anna Schuh, Lydia Scarfò

Updates in CLL from EHA 2024: combinations of BTK and BCL2 inhibitors, BTK degraders, and more

Lydia Scarfò, Toby Eyre

Updates in the treatment of CLL from EHA 2024

Toby Eyre, Lydia Scarfò

Roundtable Discussions from IBC 2024

Matthew Davids, Erin Parry, Carsten Niemann, Stephen Ansell, Paolo Ghia, Andrew Rawstron, Anton Langerak

Updates in BTK inhibitors from EHA 2023

Lydia Scarfò, Othman Al-Sawaf

Key highlights from ASH 2022

Matthew Davids, Lindsey Roeker

Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis

Matthew Davids, Lindsey Roeker

Key highlights from SOHO 2022

Nitin Jain, Catherine Coombs

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

John Gribben, David Maloney, Noelle Frey

Exploring the potential of CAR-T therapy in CLL

John Gribben, Saar Gill, Mazyar Shadman

CLL updates from iwCAR-T 2022

John Gribben, Mazyar Shadman, Saar Gill

Updates in CLL: key clinical trials in the frontline and R/R setting, pre-clinical data and MRD

Jennifer Woyach, Adam Kittai

Exploring key ASH 2021 clinical trials in the frontline and R/R setting

Adam Kittai, Jennifer Woyach

Post-EHA/ICML 2021

Paolo Ghia, Susan O’Brien, Lydia Scarfò, Othman Al-Sawaf

Post-ASH 2020

John Gribben, Alessandra Tedeschi, Meghan Thompson, Matthew Davids

ASCO & EHA 2020

John Gribben, Susan O’Brien, Matthew Davids, Barbara Eichhorst

Day 1 round up: CAR-T toxicity

John Gribben, David Maloney, Noelle Frey

CLL and CAR-T

Saar Gill, Tanya Siddiqi, Jordan Gauthier

Highlights from iwCLL 2019: MRD and novel therapies

William Wierda, Lydia Scarfò

Predictors in the novel therapy era

John Seymour, Richard Rosenquist

Varying efficacies of combination and monotherapies in CLL

Constantine Tam, Alessandra Tedeschi

Assessing the role of CAR-T in CLL

David Maloney, Johannes Schetelig

MRD assessment and the treatment of patients in the 'real world'

Barbara Eichhorst, Arnon Kater, Thomas Kipps

CLL biology and patient stratification

Barbara Eichhorst, Arnon Kater, Thomas Kipps

WM: BTK inhibitors

Ramon Garcia-Sanz, Jorge Castillo

How can doctors help empower CLL patients?

Constantine Tam, Matthew Davids, Deborah Henderson

Evolving CLL treatments: creating choices and igniting discussions

Michael Hallek, Deborah Henderson

2 years on: Deborah discusses her venetoclax trial and becoming MRD negative

John Gribben, Deborah Henderson

Looking beyond the leukemic cell for answers

Christopher Pepper, Ingo Ringshausen, Martina Seiffert

Inherited and acquired genetic factors involved in the development of CLL

Stephan Stilgenbauer, John Gribben, Olivier A. Bernard

Promising future leaders in CLL research

Jacqueline Barrientos, Pablo Oppezzo, Shih Shih Chen

Why should young investigators join the CLL community?

Constantine Tam, Matthew Davids

Diagnosis and Initial Treatment of CLL

Peter Hillmen, Richard Furman, Stephan Mulligan

Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL

Stephan Stilgenbauer, John Gribben

Is the era of chemotherapy over in CLL?

Stephan Stilgenbauer, John Gribben

Combination treatment regimens for CLL

Stephan Stilgenbauer, John Gribben

The promise of second-generation PI3K inhibitors for CLL

Stephan Stilgenbauer, John Gribben

Can we afford to have CLL patients on a therapy for the rest of their lives?

Stephan Stilgenbauer, John Gribben

Overview of RESONATE-2 clinical trial of ibrutinib in CLL

Stephan Stilgenbauer, John Gribben

Importance of Bcl-2-targeted therapies

Stephan Stilgenbauer, John Gribben

Highlights of ASH in CLL

Stephan Stilgenbauer, John Gribben

Phase II trial of venetoclax monotherapy for relapsed/refractory CLL with 17p deletion

Stephan Stilgenbauer, John Gribben

Updates in CLL

John Gribben, Tanya Siddiqi, Joseph Melenhorst

Latest advances in BTK inhibitors from EHA 2023

Lydia Scarfò, Othman Al-Sawaf

MBL: biology, classification & the possibility of early interception

Paolo Ghia, Stephen Ansell, Andrew Rawstron, Anton Langerak

Richter’s transformation: biology & ongoing trials in the field

Carsten Niemann, Matthew Davids, Erin Parry

An update on CAR-T in CLL

Saar Gill, Tanya Siddiqi

CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products

Catherine Bollard, Stephen Schuster, Jason Westin

Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders

Tanya Siddiqi, Krish Patel, Alexey Danilov

CLL updates from SOHO 2022: novel treatment strategies, the promise of next-generation BTK inhibitors & more

Nitin Jain, Catherine Coombs

Day 1 round up: CAR T-cell products

John Gribben, David Maloney, Noelle Frey

iwCLL – International Workshop on Chronic Lymphocytic Leukemia

Peter Hillmen, Michael Hallek, Jacqueline Barrientos, Stephan Stilgenbauer, John Gribben, Federico Caligaris-Cappio, Kanti Rai, Freda Stevenson, Thomas Kipps

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

The value and mission of the International Workshop on Acute Leukemias

Marina Konopleva, Charles Craddock, Naval Daver

Immunotherapy in AML: translational insights and promising avenues being explored

Marion Subklewe, John DiPersio, Jeffrey S. Miller, Nelli Bejanyan, Ann-Kathrin Eisfeld

Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies

Andrew Wei, Eunice Wang, David Sallman, Gabriel Mannis

Debate: the value and utility of MRD in the management of adults with newly-diagnosed AML

Mark Levis, Eunice Wang, Sanam Loghavi

iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more

Marina Konopleva, Harry Erba, Thomas Cluzeau, Aditi Shastri

Is pre-transplant intervention warranted in patients with MRD-positive AML?

Eytan Stein, Maximilian Stahl

Menin inhibitors in AML: combinations, resistance, and future directions

Amir Fathi, Eytan Stein, Naval Daver, Joshua Zeidner

T-cell engagers and CARs in myeloid malignancies

Marion Subklewe, Jae Park, David Sallman, Andrew Kuykendall

Menin inhibition in AML: clinical guidance and future directions

Charles Craddock, Curtis Lachowiez

Venetoclax resistance in AML: mechanisms and strategies to overcome

Daniel Pollyea, Curtis Lachowiez

Menin inhibition in AML: clinical guidance and future directions

Charles Craddock, Curtis Lachowiez

Venetoclax resistance in AML

Daniel Pollyea, Curtis Lachowiez

A study investigating long-term survivorship outcomes in AML

Klaus Metzeler, Eva Telzerow

Prolonging remission in AML: current approaches & future outlooks

Harry Erba, Thomas Cluzeau, Farhad Ravandi

Discovery of a new predisposition gene, ERG, for bone marrow failure and hematological malignancy

Hamish Scott, Chris Hahn

iwAL 2023

Ravi Majeti, Uma Borate, Koichi Takahashi, Courtney DiNardo, Naval Daver, Gail Roboz, Harry Erba, Jessica Altman, Eunice Wang, Thomas Cluzeau, Marina Konopleva, Andrew Wei, Sanam Loghavi, Aditi Shastri, Charles Craddock, David Sallman, Mark Levis, Nelli Bejanyan

Improving transplantation outcomes in AML

Charles Craddock, Christopher Hourigan

iwAL 2022

Mark Levis, Eunice Wang, Jessica Altman, Charles Craddock, Richard Stone, David Sallman, Thomas Cluzeau, Naval Daver, Paresh Vyas, Alexander Perl, Carsten Müller‐Tidow, Saar Gill, Marion Subklewe, Amer Zeidan

Addressing the major challenges to CAR-T therapy in AML

John DiPersio, Saar Gill, Rizwan Romee

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

John Gribben, David Maloney, Noelle Frey

AML updates from iwCAR-T 2022

Saar Gill, John DiPersio, Rizwan Romee

Updates in FLT3+ from ASH 2021

Naval Daver, Eunice Wang

Discussing FLT3-mutated AML: top ASH data, triplets, and exciting future strategies

Naval Daver, Eunice Wang

Post-EHA/ASCO 2021

Naval Daver, Eunice Wang, Felicitas Thol

Prognostic relevance of monocytic switch and future research

Ester Mejstříková, Michaela Nováková

Post-ASH 2020

Naval Daver, David Sallman, Eunice Wang, Amir Fathi

FLT3-Mutated AML

Naval Daver, Amir Fathi, Eunice Wang

Venetoclax-Based Regimens

Naval Daver, Courtney DiNardo, Marina Konopleva, Andrew Wei

IDH Inhibitors

Amir Fathi, Stéphane de Botton, Daniel Pollyea

Immunotherapy

Marion Subklewe, Naval Daver, David Sallman, Amer Zeidan

EHA & ASCO 2020

Naval Daver, Marion Subklewe, Andrew Wei, Amir Fathi

Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

John Gribben, David Maloney, Saar Gill

Acute leukemias: is MRD already a surrogate for survival?

Marion Subklewe, Farhad Ravandi, Adriano Venditti

MRD for acute leukemias: opinion from both sides of the Atlantic

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

Challenging the norms for elderly AML treatment: clinical trials & intensive therapy

Klaus Metzeler, Wolfgang Hiddemann, Alan Burnett, Laura Cicconi

ASH 2014: Ask the experts Q&A session 2

David Steensma, Christoph Röllig, Brent Wood, Wendy Stock, Oliver Ottmann, Eytan Stein

Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease

Marina Konopleva, Richard Stone, Thomas Cluzeau

Discussion: should less intensive therapy be used in all older newly diagnosed pts with AML, even if fit for intensive chemo?

Eunice Wang, Tapan Kadia, Jessica Altman

Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs

Andrew Wei, Farhad Ravandi, David Sallman, Sanam Loghavi

AML treatment: what does the data say?

Christoph Röllig, Adriano Venditti, Richard Larson

Biological mechanisms of AML: a 2019 update

Klaus Metzeler, Mark Levis, Ravi Majeti

Standard of care in AML in 2022

Charles Craddock, Mark Levis, Eunice Wang, Jessica Altman

Novel targets, treatments, and combinations in AML

Richard Stone, David Sallman, Thomas Cluzeau

What do we know about drug resistance in AML?

Naval Daver, Alexander Perl, Paresh Vyas, Carsten Müller‐Tidow

Immunotherapeutics in AML

Marion Subklewe, Saar Gill, Amer Zeidan

Current challenges in clinical genomics

Andrew Wei, Paresh Vyas, Jean Soulier

Improving transplant outcomes in AML

Charles Craddock, Christopher Hourigan

iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML

Andrew Wei, Mark Levis, Stéphane de Botton, Richard Stone

Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones

Klaus Metzeler, Mark Levis, Ari Melnick, Torsten Haferlach

Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?

Klaus Metzeler, Mark Levis, Ari Melnick, Torsten Haferlach

Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy

Klaus Metzeler, Wolfgang Hiddemann, Alan Burnett, Laura Cicconi

Novel targets, combinations & treatments

Marina Konopleva, Eunice Wang, Thomas Cluzeau

The future treatment of acute leukemias: part II

Andrew Wei, Mark Levis, Alan Burnett

The future treatment of acute leukemias: part I

Andrew Wei, Mark Levis, Alan Burnett

Novel approaches and targeted therapies in 2019 for AML

Andrew Wei, Mark Levis, Torsten Haferlach

iwAL 2019: CAR-T & cellular therapies in AML and ALL

Wendy Stock, Noelle Frey, Bianca Santomasso

Updates in AML

Marion Subklewe, David Sallman, Roman Shapiro

AML highlights from iwCAR-T 2023

Marion Subklewe, David Sallman

Clonal hematopoiesis, early detection & potential therapeutics

Ravi Majeti, Uma Borate, Courtney DiNardo, Koichi Takahashi

New treatments in AML: FLT3 inhibitors & novel combinations

Harry Erba, Gail Roboz, Naval Daver, Jessica Altman

TP53 mutation in AML

Andrew Wei, Sanam Loghavi

Immunotherapy for AML & ALL

Marion Subklewe, Richard Stone, Ivana Gojo

Transplantation & immunotherapies

Charles Craddock, Mark Levis, David Sallman, Nelli Bejanyan

Utilizing MRD for AML in the clinical setting

Marion Subklewe, Jorge Sierra, Sylvie Freeman

The future of CAR-T therapy in AML

David Sallman, Fabiana Perna

Approaching TP53-mutated MDS and secondary AML

David Sallman, Thomas Cluzeau, Coleman Lindsley

Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more

Gail Roboz, Amy DeZern, Marie Sebert, Yazan Madanat

Ongoing research in the NIH Myeloid Malignancies Program

Response assessment & regulatory considerations in MDS

Rami Komrokji, Andrew Brunner, Lisa Pleyer, Katharina Götze

Current data on menin inhibition in AML

Eunice Wang, Joshua Zeidner

Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

Refining the diagnosis and classification of CMML

Sanam Loghavi, Guillermo Montalban-Bravo

iwMDS wrap-up: translating research into practice to optimize patient care

Amer Zeidan, Andrew Brunner, Lisa Pleyer, Elizabeth Griffiths, Yasushi Miyazaki

Evolving strategies in clinical trial design for MDS: defining response criteria

Rami Komrokji, Maximilian Stahl, Coleman Lindsley

Novel targets in MDS: telomerase inhibition, the SELECT-MDS-1 trial, PK agonists, & more

Amy DeZern, Hetty Carraway

Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more

Mikkael Sekeres, Lionel Ades, Andrew Brunner

Advances made in MDS classification and risk stratification: ongoing work & future perspectives

Uma Borate, Robert Hasserjian, Zhuoer Xie, Luca Lanino

Novel developments in lower-risk MDS & important practical considerations when treating patients

Amer Zeidan, Rena Buckstein, Guillermo Garcia-Manero, Andrew Brunner

The i4MDS consortium and immune monitoring in MDS

Sanam Loghavi, Shahram Kordasti

The i4MDS consortium and immune monitoring in MDS

Shahram Kordasti, Sanam Loghavi

Treating lower-risk MDS beyond ESA failure

Amer Zeidan, Valeria Santini, Courtney DiNardo

Treating lower-risk MDS: practical management of anemia

Amer Zeidan, Sophie Park, Yasmin Abaza, Maximilian Stahl

TP53 mutation in MDS

Amer Zeidan, Matteo Della Porta, Naval Daver, Tariq Kewan

Novel agents being explored in lower- and higher-risk MDS

Amer Zeidan, Maximilian Stahl, Jan Philipp Bewersdorf, Yasmin Abaza, Yazan Madanat

Roundtable discussions from IBC 2024

Kelly Bolton, Uma Borate, Eric Padron, George Vassiliou, Lachelle Weeks, Mrinal Patnaik

Discovery of a new predisposition gene, ERG, for bone marrow failure and hematological malignancy

Hamish Scott, Chris Hahn

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

Sanam Loghavi, Rami Komrokji

Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS

Valeria Santini, Amer Zeidan

Comparing the ICC and WHO classifications for MDS & their impact on clinical practice

Amer Zeidan, Sanam Loghavi, Somedeb Ball, Rami Komrokji

Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more

David Sallman, Andrew Brunner

Key highlights from ASH 2022

David Sallman, Andrew Brunner

iwMDS 2022

Mrinal Patnaik, Zhuoer Xie, Eric Padron, Amer Zeidan, Valeria Santini, Rena Buckstein, Hetty Carraway, Olatoyosi Odenike, Justin Taylor, Aziz Nazha, Jane Churpek, Rafael Bejar, Robert Hasserjian, Alan List, Uwe Platzbecker, Daniel Starczynowski, David Sallman

Addressing the major challenges to CAR-T therapy in AML

John DiPersio, Saar Gill, Rizwan Romee

The impact of AI in MDS

Amer Zeidan, Aziz Nazha, Anne Sophie Kubasch

What did ASH 2021 mean for MDS?

David Sallman, Andrew Brunner

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

David Sallman, Andrew Brunner

Post-EHA/ASCO 2021

Amer Zeidan, Andrew Wei, David Sallman

Women in Science

Amer Zeidan, Valeria Santini, Eva Hellström-Lindberg

Giants in MDS

Amer Zeidan, Peter Greenberg, Mario Cazzola, John Bennett, Ghulam Mufti

Diagnosis & Prognosis

Global Perspectives

Amer Zeidan, Anne Mwirigi, Mariana Guaraná, Rishi Dhawan, Iman Aboudalle

Post-ASH 2020

Amer Zeidan, Uwe Platzbecker, Jacqueline Garcia

Lower-Risk Disease

Amer Zeidan, Valeria Santini, Rami Komrokji, Olatoyosi Odenike

Latest Updates

Amer Zeidan, Amy DeZern, Michael Savona, Mikkael Sekeres, David Steensma

Response assessment & regulatory considerations in MDS

Rami Komrokji, Andrew Brunner, Lisa Pleyer, Katharina Götze

Inflammation, immune dysregulation and targeting in MDS

Alan List, David Sallman, Uwe Platzbecker, Daniel Starczynowski

Updates in classification and risk stratification in MDS

Rafael Bejar, Aziz Nazha, Jane Churpek, Robert Hasserjian

Clonal hematopoiesis and pre-MDS states

Zhuoer Xie, Mrinal Patnaik, Eric Padron

How can we improve the efficiency of drug approval in MDS?

Olatoyosi Odenike, Andrew Brunner, Hetty Carraway, Justin Taylor

Key highlights from iwMDS 2022

Valeria Santini, Amer Zeidan, Rena Buckstein

Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS

Valeria Santini, Amer Zeidan

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

Rami Komrokji, Sanam Loghavi

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

Marina Konopleva, Anand Patel, Guillermo Montalban-Bravo, Emma Groarke

Updates on established therapies in AML - Part 1

Eytan Stein, Tara Lin, Tapan Kadia, Maximilian Stahl

Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks

Claire Harrison, Naveen Pemmaraju, John Mascarenhas, Daniel Wiseman

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists

Uma Borate, Kelly Bolton, Eric Padron

Updates in the diagnosis, classification & risk stratification of MDS

Christopher Hourigan, Maria Teresa Voso, Robert Hasserjian, Somedeb Ball

Aiming to advance the diagnosis and treatment of CMML and BPDCN

John Bennett, Daniel Wiseman, Mrinal Patnaik

Ongoing research in the NIH Myeloid Malignancies Program

Updates in LR-MDS treatment: imetelstat and luspatercept, standardizing PROs, and using AI to improve risk stratification

Amer Zeidan, Uwe Platzbecker, Fabio Efficace, Hetty Carraway, Adrián Mosquera Orgueira

Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more

Andrew Wei, Amer Zeidan, Uwe Platzbecker, Aditi Shastri

Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more

Gail Roboz, Amy DeZern, Marie Sebert, Yazan Madanat

New directions and governmental progress in MDS: insights into MyeloMATCH & CTEP

Olatoyosi Odenike, Maximilian Stahl, Elizabeth Griffiths, Steven Gore

New trends in CHIP/CCUS: impact of CH on transplant outcomes & distinguishing between MDS & CCUS

Uma Borate, Lachelle Weeks, Coleman Lindsley

Approaching TP53-mutated MDS and secondary AML

David Sallman, Thomas Cluzeau, Coleman Lindsley

CHIP: clinical relevance, challenges & preventing myeloid malignancies

Mrinal Patnaik, George Vassiliou, Lachelle Weeks

The future of CAR-T therapy in AML

David Sallman, Fabiana Perna

Myeloproliferative Neoplasms (MPNs)

Myeloproliferative Neoplasms (MPNs)

Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more

Adam Mead, Juan Carlos Hernández-Boluda, Charlotte Brierley

Challenging and uncommon scenarios in MPNs

Claire Harrison, Deepti Radia, Andreas Reiter, Nicola Polverelli

Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity

David Steensma, Shahram Kordasti

Novel approaches to upfront management of myelofibrosis

Haifa Kathrin Al-Ali, Donal McLornan, Prithviraj Bose

T-cell engagers and CARs in myeloid malignancies

Marion Subklewe, Jae Park, David Sallman, Andrew Kuykendall

Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms

Alex Rampotas, Zoë Wong

The inaugural MPN Workshop of the Carolinas: the importance of the meeting for the MPN community

Naveen Pemmaraju, Ruben Mesa

Key highlights from ASH 2023

Ruben Mesa, Claire Harrison, Jean-Jacques Kiladjian

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more

Claire Harrison, Ruben Mesa, Jean-Jacques Kiladjian

Key highlights from ASH 2022

Aaron Gerds, Lucia Masarova

Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy

Aaron Gerds, Lucia Masarova

Drivers of progression in MPNs and the importance of early intervention

Angela Fleischman, Andrew Kuykendall

Key updates from the 2022 Texas MPN Workshop

Ruben Mesa, Naveen Pemmaraju

Key updates from EHA 2022

Ruben Mesa, Claire Harrison, Jean-Jacques Kiladjian

Key takeaways in MPNs

Naveen Pemmaraju, Ruben Mesa

Key updates from ASH 2021

Ruben Mesa, Naveen Pemmaraju

Post-EHA/ASCO 2021

Ruben Mesa, Naveen Pemmaraju

Post-ASH 2020

Ruben Mesa, Srdan Verstovsek, Claire Harrison, Naveen Pemmaraju

2020 Texas MPN Workshop

Naveen Pemmaraju, Ruben Mesa, Claire Harrison

Aiming to advance the diagnosis and treatment of CMML and BPDCN

John Bennett, Daniel Wiseman, Mrinal Patnaik

Unmet needs in MF and focusing on early intervention in patients with MPNs

Claire Harrison, Naveen Pemmaraju, Aaron Gerds, Abdulraheem Yacoub

Day 1 highlights: imetelstat in MF, challenges with MPN/MDS overlap syndromes & future outlooks

Claire Harrison, Naveen Pemmaraju, John Mascarenhas, Daniel Wiseman

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

Marina Konopleva, Anand Patel, Guillermo Montalban-Bravo, Emma Groarke

Updates in LR-MDS treatment: imetelstat and luspatercept, standardizing PROs, and using AI to improve risk stratification

Amer Zeidan, Uwe Platzbecker, Fabio Efficace, Hetty Carraway, Adrián Mosquera Orgueira

Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more

Kristen Pettit, Lucia Masarova, Andrew Kuykendall

Key highlights from the 2022 Texas MPN Workshop

Naveen Pemmaraju, Ruben Mesa

MPN Sessions: Key updates from EHA 2022

Claire Harrison, Ruben Mesa, Jean-Jacques Kiladjian

Considering the use of symptom response as an endpoint in myelofibrosis clinical trials

Lymphoma

Lymphoma

Advances in mantle cell lymphoma treatment - insights from TRIANGLE, BTKis, and the changing role of SCT

Martin Dreyling, Georg Hess

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL

Martin Hutchings, Elizabeth Budde, Lorenzo Falchi, Sameh Gaballa

An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials

Meghan Thompson, Alexey Danilov

Expanding the CAR platform for NHL

Catherine Bollard, Tanya Siddiqi, Mazyar Shadman, Connor Johnson

Novel therapies and ongoing trials in NHL: advances in antibody-based combinations

Laurie Sehn, Gilles Salles, Juan Alderuccio

Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more

Stephen Ansell, Michael Wang, Tycel Phillips

Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists

Paolo Strati, Evandro Bezerra, Andrew Jallouk

Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy

Elizabeth Budde, Michael Jain, Marco Ruella, Mohammad Rashidian

Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics

Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more

Saar Gill, Francesco Maura, Maik Luu, Ciara Freeman

CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations

Tycel Phillips, Krish Patel, Alexey Danilov

Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more

Paolo Strati, Manali Kamdar, Gloria Iacoboni

Sequencing therapies in R/R DLBCL, MCL & FL

Manali Kamdar, Paolo Strati, Gloria Iacoboni

The value of BTK inhibitors in the treatment of frontline and relapsed MCL: expert insights

Tycel Phillips, Krish Patel, Craig Portell

Evaluating the role of stem cell transplantation vs CAR-T therapy in LBCL

Paolo Strati, Evandro Bezerra, Andrew Jallouk

Exploring the role of BTK inhibitors in frontline and R/R mantle-cell-lymphoma

Krish Patel, Craig Portell, Tycel Phillips

A European study investigating patient-reported outcomes of CAR T-cell therapy

Anne Spanjaart, Elise Pennings

The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks

Tycel Phillips, Manali Kamdar

Roundtable discussions from IBC 2024

Jessica Okosun, Anna Schuh, Sandrine Roulland

iwNHL 2023

Martin Hutchings, Marion Subklewe, Mazyar Shadman, Krish Patel, Tanya Siddiqi, Nirav Niranjan Shah, David Maloney, Jason Westin, David Miklos, John Gribben, Laurie Sehn, Andrew Davies, Sven De Vos, Ash Alizadeh, Laura Pasqualucci, Ken Young, Stephen Ansell, John Kuruvilla, Marek Trněný, Yucai Wang, Francine Foss, Steven Horwitz, Laurence de Leval, François Lemonnier

PDX mice as representative models for T-cell lymphoma

Luca Cappelli, Danilo Fiore

Updates in CAR-T & bispecific antibodies from EHA 2023

Gloria Iacoboni, Paolo Strati

Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies

Michael Dickinson, Tycel Phillips

Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks

Kate Cwynarski, Swaminathan Iyer

Key highlights in T-cell lymphoma from ASH 2022

Kate Cwynarski, Swaminathan Iyer

Key highlights in NHL from ASH 2022

Michael Dickinson, Tycel Phillips

iwNHL 2022

Laurence de Leval, Steven Horwitz, John Gribben, Stephen Ansell, John Kuruvilla, Laura Pasqualucci, Jessica Okosun, Catherine Bollard, Jeremy Abramson, Barbara Savoldo, Maksim Mamonkin, Laurie Sehn, Carmelo Carlo-Stella, David Straus, Marion Subklewe, Loretta Nastoupil, Rajat Bannerji, Marek Trněný, David Maloney

Key updates in lymphoma and impact on UK clinical practice

Graham Collins, Wendy Osborne, Andrew Davies

Upcoming trials and agents in T-cell lymphoma

Kate Cwynarski, Gloria Iacoboni

Advances in CAR-T therapy for lymphoma

David Maloney, Caron Jacobson, Loretta Nastoupil

Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma

Yi Lin, Suzanne Trudel, Frederick Locke, Krina Patel

Lymphoma updates from iwCAR-T 2022

David Maloney, Caron Jacobson, Loretta Nastoupil

Updates from the lymphoma & CLL session: clinical trials, novel agents, and more

Andrew Davies, Kate Cwynarski

CAR-T and lymphoma treatment in the UK

Robin Sanderson, Tobias Menne

Post-ASH 2021

Wendy Osborne, Graham Collins

Highlighting unmet needs for CTCL

Marios Koumourtzis, Evangelina Papadavid

Post-EHA/ICML 2021

Gilles Salles, Nirav Niranjan Shah, Ulrich Jäger, Stephen Ansell

Post-ASH 2020 UK

Graham Collins, Wendy Osborne

Post-ASH 2020

Stephen Ansell, Graham Collins

Expert discussion on CAR-T updates in lymphoma

Ian Flinn, Caron Jacobson, Stephen Schuster, Frederick Locke

Day 1 round up: CAR-T toxicity

John Gribben, David Maloney, Noelle Frey

Current frontline treatment for WM

Ramon Garcia-Sanz, Jorge Castillo

WM: BTK inhibitors

Ramon Garcia-Sanz, Jorge Castillo

Targeted therapy in MM

Rafael Fonseca, Enrique Ocio, Sagar Lonial

Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?

John Gribben, Margaret Shipp

iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine

John Gribben, Anas Younes, Caron Jacobson

Cellular therapy and drug access for viral lymphomas

Catherine Bollard, Mark Roschewski, Ruth Jarrett, Richard Little

Precision medicine in lymphoma

Anas Younes, Davide Rossi, Thomas Witzig

Viral lymphomas: risk factors and treatments

Catherine Bollard, Mark Roschewski, Ruth Jarrett, Richard Little

CAR T-cells in lymphoma: where are we now?

James Kochenderfer, David Maloney, William Go, Stephen Schuster

iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine

John Gribben, Stephen Ansell, Catherine Bollard

Immunotherapy for NHL: checkpoint inhibitors, considerations & the future

John Gribben, Stephen Ansell, Robert Chen

Novel diagnostics & biomarkers for DLBCL and CTCL

Bjoern Chapuy, Thomas Habermann, Nicolas Ortonne

Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

How immunotherapies are re-shaping the treatment of lymphoma

Stephen Ansell, Catherine Bollard, Steve Gottschalk

Describing clonal evolution in lymphoma

Michael Pfreundschuh, Ryan Morin, Reiner Siebert, Robert Kridel

iwNHL 2016: Highlights from Day 1

John Gribben, Catherine Bollard, Wyndham Wilson, Laurence de Leval

Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure

Nathan Fowler, Anas Younes, James Kochenderfer, David Maloney

Panel discussion on mantle cell lymphoma

Simon Rule, Constantine Tam, Mary Callanan

Novel targets and agents for lymphoma

Kieron Dunleavy, Laurie Sehn, John Kuruvilla

Lymphoma Sessions: CAR-T and lymphoma treatment in the UK

Robin Sanderson, Tobias Menne

Evolving treatment landscape of MCL

Stephen Ansell, Marek Trněný, John Kuruvilla, Yucai Wang

iwNHL 2017: The future of lymphoma research and treatment

John Gribben, Owen O'Connor, Catherine Bollard, Laurie Sehn

Novel lymphoma targets and agents

Andrew Zelenetz, Laurie Sehn

12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights

John Gribben, Anton Hagenbeek, Wyndham Wilson, Michael Pfreundschuh, Myron Czuczman

Novel therapies in NHL: BTK inhibitors & degraders

Tanya Siddiqi, Nirav Niranjan Shah

Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents

John Kuruvilla, Michael Wang, Caron Jacobson

ADCs in B-cell lymphomas: emerging data and novel targets

Laurie Sehn, Paolo Caimi, Alex Herrera, Juan Alderuccio

Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders

Tanya Siddiqi, Krish Patel, Alexey Danilov

Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023

Paolo Strati, Gloria Iacoboni

T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1

Laurence de Leval, Francine Foss, David Weinstock, Lucy Cook

The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization

Nathan Fowler, Laura Pasqualucci, Robert Kridel

The need for academic and pharmaceutical collaboration in drug development

John Gribben, Jay Bradner

Will knowledge of the molecular pathology of lymphoma improve clinical trials?

John Gribben, David Maloney, Laurie Sehn

CAR-T vs bispecific antibodies for lymphoma

John Gribben, David Maloney, Laurie Sehn

Day 1 round up: CAR T-cell products

John Gribben, David Maloney, Noelle Frey

Pathobiology and clinical management of T-cell lymphoma

Francine Foss, Jürgen Ruland

Lymphoma CAR and bispecific updates

Loretta Nastoupil, Tycel Phillips, Mazyar Shadman

Updates in T-cell leukemia/lymphoma

Francine Foss, Lucy Cook, Kate Cwynarski, Thierry Lamy

Updates on the biology and treatment of T-cell lymphoma

Laurence de Leval, Francine Foss, Steven Horwitz, François Lemonnier

New therapeutic targets in DLBCL

Ash Alizadeh, Laura Pasqualucci, Ken Young

Expanding the CAR platform in NHL

David Maloney, David Miklos, Jason Westin

CAR-T for lymphoma: new targets, real world data & resistance

Catherine Bollard, David Maloney, Barbara Savoldo, Maksim Mamonkin

Bispecific antibodies in NHL

Marion Subklewe, Martin Hutchings, Mazyar Shadman, Krish Patel

Novel therapies in NHL: antibody-drug conjugates

Andrew Davies, John Gribben, Laurie Sehn, Sven De Vos

Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches

Marion Subklewe, Stephen Ansell, Martin Hutchings, Krish Patel

CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products

Catherine Bollard, Stephen Schuster, Jason Westin

Cellular Therapy Sessions

Cellular Therapy Sessions

Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting

Peter Voorhees, Holly Lee

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more

Kenneth Anderson, Francesco Maura, Mehmet Samur

Expanding the CAR platform for NHL

Catherine Bollard, Tanya Siddiqi, Mazyar Shadman, Connor Johnson

Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists

Paolo Strati, Evandro Bezerra, Andrew Jallouk

Immunotherapy in AML: translational insights and promising avenues being explored

Marion Subklewe, John DiPersio, Jeffrey S. Miller, Nelli Bejanyan, Ann-Kathrin Eisfeld

Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies

Andrew Wei, Eunice Wang, David Sallman, Gabriel Mannis

Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity

David Steensma, Shahram Kordasti

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease

Arnon Kater, Paolo Ghia

Important considerations for community oncologists regarding the use of T-cell therapies in myeloma

Rachid Baz, Damian Green

T-cell engagers and CARs in myeloid malignancies

Marion Subklewe, Jae Park, David Sallman, Andrew Kuykendall

Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy

Elizabeth Budde, Michael Jain, Marco Ruella, Mohammad Rashidian

Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics

CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations

Tycel Phillips, Krish Patel, Alexey Danilov

Improving access and delivery of CAR T-cells and bispecific antibodies in the community

Caron Jacobson, Krish Patel, Tara Graff

Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more

Yi Lin, Rakesh Popat, Sham Mailankody, Doris Hansen

Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more

Saar Gill, Francesco Maura, Maik Luu, Ciara Freeman

Integrating autoimmune diseases into cellular therapy centers

Frederick Locke, David Miklos, Lazaros Lekakis, Sarah Nikiforow

CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more

Noelle Frey, Bijal Shah, Claire Roddie, Rebecca Gardner

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

David Maloney, Mazyar Shadman, Alexey Danilov

Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more

Paolo Strati, Manali Kamdar, Gloria Iacoboni

A European study investigating patient-reported outcomes of CAR T-cell therapy

Anne Spanjaart, Elise Pennings

Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms

Alex Rampotas, Zoë Wong

Looking forward to the EBMT 2023 Trainee Day

Nico Gagelmann, Claire Horgan

iwCAR-T 2023

Marco Davila, Filip Ionescu, Michael Green, Evan Weber, Bianca Santomasso, Matthew Frigault, Bijal Shah, Claire Roddie, Rebecca Gardner, David Sallman, Roman Shapiro, Marion Subklewe, Loretta Nastoupil, Mazyar Shadman, Tycel Phillips, Caron Jacobson, Valentín Ortiz-Maldonado, Rafael Fonseca, Yi Lin, Nizar Bahlis, Sham Mailankody, John Gribben, Tanya Siddiqi, Joseph Melenhorst

Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks

Kate Cwynarski, Swaminathan Iyer

Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies

Michael Dickinson, Tycel Phillips

Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks

Yi Lin, Krina Patel

Upcoming trials and agents in T-cell lymphoma

Kate Cwynarski, Gloria Iacoboni

Patient-reported outcomes in CAR-T recipients

Heather Jim, Kedar Kirtane, Laura Oswald

Exploring the potential of CAR-T therapy in CLL

John Gribben, Saar Gill, Mazyar Shadman

Addressing the major challenges to CAR-T therapy in AML

John DiPersio, Saar Gill, Rizwan Romee

The future of CAR-T therapy in ALL

Noelle Frey, Bijal Shah, Shannon Maude

Day 2 wrap-up: pushing myeloma boundaries

Rafael Fonseca, Gareth Morgan, Keith Stewart, Leif Bergsagel

T-Cell Engagers: targets, challenges and opportunity

Thomas Martin, Hermann Einsele, Nina Shah

Novel targets in 2022

Faith Davies, Hearn Jay Cho, Charlotte Pawlyn

Genomics in the age of I-O

Gareth Morgan, Francesco Maura, Leo Rasche

EBMT Trainee Committee & Young EHA Ambassadors: educating trainees about CAR-T

Nico Gagelmann, Claire Horgan

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

David Sallman, Andrew Brunner

Next steps for myeloma research and treatment

Faith Davies, Gareth Morgan

Patient segmentation for targeted therapy in myeloma

Faith Davies, Gareth Morgan

The new era of myeloma therapies

Irene Ghobrial, Maria Victoria-Mateos

Precursor conditions: management of smoldering myeloma

Irene Ghobrial, Maria Victoria-Mateos

Long-term disease-free survival in myeloma

Heinz Ludwig, Hermann Einsele

Expert discussion on CAR-T updates in lymphoma

Ian Flinn, Caron Jacobson, Stephen Schuster, Frederick Locke

Toxicity issues with CAR T-cell therapy

Noelle Frey, Bianca Santomasso, Daniel Lee

What's the latest on CAR-T in ALL?

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

CLL and CAR-T

Saar Gill, Tanya Siddiqi, Jordan Gauthier

CAR T-cell therapy in myeloma

Edward Stadtmauer, Yi Lin, Krina Patel

Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

John Gribben, David Maloney, Saar Gill

Day 1 round up: CAR-T toxicity

John Gribben, David Maloney, Noelle Frey

Assessing the role of CAR-T in CLL

David Maloney, Johannes Schetelig

MRD evaluation: a key component of MM management?

Mohamad Mohty, Elena Zamagni, Joaquin Martinez-Lopez

CAR-T: hurdles and ladders

Faith Davies, Noopur Raje, David Avigan, Adam Cohen

Targeted therapy in MM

Rafael Fonseca, Enrique Ocio, Sagar Lonial

Immunotherapy in myeloma: current strategies and future perspectives

Niels van de Donk, Saad Usmani, Ajai Chari

iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine

John Gribben, Anas Younes, Caron Jacobson

CAR T-cells in lymphoma: where are we now?

James Kochenderfer, David Maloney, William Go, Stephen Schuster

Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance

Keith Stewart, Thomas Martin, Florian Bassermann

CAR T-cells in myeloma: exploratory targets & payment models

Andrew Spencer, Ravi Vij, David Siegel

Where in the treatment sequence should CAR T-cells be used for myeloma?

Andrew Spencer, Ravi Vij, David Siegel

Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Gareth Morgan, Keith Stewart, Leif Bergsagel

The use of CAR T-cells in multiple myeloma

Yi Lin, Adam Cohen, Sabrina Prommersberger

How immunotherapies are re-shaping the treatment of lymphoma

Stephen Ansell, Catherine Bollard, Steve Gottschalk

Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure

Nathan Fowler, Anas Younes, James Kochenderfer, David Maloney

Myeloma 2016: Panel discussion on gene modified T-cells

James Kochenderfer, Edward Stadtmauer, Michael Hudecek, Ivan Borrello

Myeloma 2016: Panel discussion on novel treatments

Keith Stewart, Sagar Lonial, Leif Bergsagel, Kenneth Anderson

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs

James Kochenderfer, Adam Cohen, Andrzej Jakubowiak

The definitive guide to multiple myeloma at ASH 2018: part IV

Mohamad Mohty, Saad Usmani

iwAL 2019: CAR-T & cellular therapies in AML and ALL

Wendy Stock, Noelle Frey, Bianca Santomasso

The future treatment of acute leukemias: part I

Andrew Wei, Mark Levis, Alan Burnett

The future treatment of acute leukemias: part II

Andrew Wei, Mark Levis, Alan Burnett

Immunotherapy for AML & ALL

Marion Subklewe, Richard Stone, Ivana Gojo

CAR-T for lymphoma: new targets, real world data & resistance

Catherine Bollard, David Maloney, Barbara Savoldo, Maksim Mamonkin

CAR-T vs bispecific antibodies for lymphoma

John Gribben, David Maloney, Laurie Sehn

Day 1 round up: CAR T-cell products

John Gribben, David Maloney, Noelle Frey

Updates in AML

Marion Subklewe, David Sallman, Roman Shapiro

Rapid CAR manufacture

Caron Jacobson, Valentín Ortiz-Maldonado, Matthew Frigault

Current challenges in CAR-T

Marco Davila, Evan Weber, Filip Ionescu, Michael Green

Updates in ALL

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

Updates in CLL

John Gribben, Tanya Siddiqi, Joseph Melenhorst

Updates in multiple myeloma

Rafael Fonseca, Yi Lin, Nizar Bahlis, Sham Mailankody

Prophylaxis and management of CRS & ICANS

Bianca Santomasso, Matthew Frigault

Resistance mechanisms mediated by the microenvironment in multiple myeloma

Irene Ghobrial, Lawrence Boise, Charlotte Pawlyn, Paola Neri

The future of myeloma therapy

Brian Walker, Keith Stewart, Martin Kortüm, Claudia Stege

Novel therapeutic strategies in multiple myeloma

Enrique Ocio, Carlos Fernández De Larrea, Elena Zamagni, Nizar Bahlis

Reaching a cure for multiple myeloma

Gareth Morgan, Sagar Lonial, Pieter Sonneveld

Key myeloma highlights from EHA 2023

Jesús San Miguel, Enrique Ocio

Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023

Paolo Strati, Gloria Iacoboni

AML highlights from iwCAR-T 2023

Marion Subklewe, David Sallman

Transplantation & immunotherapies

Charles Craddock, Mark Levis, David Sallman, Nelli Bejanyan

New therapeutic targets in DLBCL

Ash Alizadeh, Laura Pasqualucci, Ken Young

Expanding the CAR platform in NHL

David Maloney, David Miklos, Jason Westin

The value of genomics in multiple myeloma & applying this in clinical practice

Gareth Morgan, Arun Wiita, Francesco Maura, Sarah Gooding

Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more

Ola Landgren, Suzanne Lentzsch, Thomas Martin, Suzanne Trudel

Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities

Faith Davies, Gareth Morgan, Louis Williams

History and upcoming projects of the MMRF

Lawrence Boise, Hearn Jay Cho

An update on CAR-T in CLL

Saar Gill, Tanya Siddiqi

CAR T-cells for autoimmune diseases

The future of CAR-T therapy in AML

David Sallman, Fabiana Perna

Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches

Marion Subklewe, Stephen Ansell, Martin Hutchings, Krish Patel

CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products

Catherine Bollard, Stephen Schuster, Jason Westin

Updates in T-cell leukemia/lymphoma

Francine Foss, Lucy Cook, Kate Cwynarski, Thierry Lamy

ADCs in B-cell lymphomas: emerging data and novel targets

Laurie Sehn, Paolo Caimi, Alex Herrera, Juan Alderuccio

Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents

John Kuruvilla, Michael Wang, Caron Jacobson

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

Marina Konopleva, Anand Patel, Guillermo Montalban-Bravo, Emma Groarke

Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies

Niels van de Donk, Thomas Martin, Saad Usmani, Ajai Chari

CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs

Ajai Chari, Krina Patel

Defining high-risk multiple myeloma: recent advances in the field & future considerations

Kenneth Anderson, Francesco Maura, Simon Harrison

Evolving treatment landscape of MCL

Stephen Ansell, Marek Trněný, John Kuruvilla, Yucai Wang

Immunotherapeutics in AML

Marion Subklewe, Saar Gill, Amer Zeidan

T-cell engagers and treating relapsed ALL

Elias Jabbour, Bijal Shah, Sabina Chiaretti, Nicolas Boissel

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population

Heinz Ludwig, Meral Beksac

The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies

Leif Bergsagel, Marta Chesi

Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies

Mohamad Mohty, Saad Usmani

Amyloidosis Sessions: Highlights from ASH 2024

Ashutosh Wechalekar, Vaishali Sanchorawala

Lymphoma Sessions: CAR-T and lymphoma treatment in the UK

Robin Sanderson, Tobias Menne

Acute lymphoblastic leukemia (ALL)

Acute lymphoblastic leukemia (ALL)

CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more

Noelle Frey, Bijal Shah, Claire Roddie, Rebecca Gardner

iwAL 2022

Sabina Chiaretti, Robin Foà, Rob Pieters, Nicholas Short, Nicolas Boissel, Dieter Hoelzer, Bijal Shah, Elias Jabbour

Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

John Gribben, David Maloney, Noelle Frey

The future of CAR-T therapy in ALL

Noelle Frey, Bijal Shah, Shannon Maude

Prognostic relevance of monocytic switch and future research

Ester Mejstříková, Michaela Nováková

Myeloid switch of B-cell precursor ALL subtypes

Ester Mejstříková, Michaela Nováková

Day 1 round up: CAR-T toxicity

John Gribben, David Maloney, Noelle Frey

What's the latest on CAR-T in ALL?

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

Assessing the role of CAR-T in CLL

David Maloney, Johannes Schetelig

The evolving genomic landscape of ALL: molecular genetics, profiling and classification

Charles Mullighan, Kathryn Roberts, Anjali Advani

Recent subtypes of ALL: Ph-like ALL and ETP ALL

Charles Mullighan, Kathryn Roberts, Anjali Advani

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL

Charles Mullighan, Daniel DeAngelo, Richard Larson

iwAL 2018: a plethora of new drugs & their impact on trial design

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

MRD for acute leukemias: opinion from both sides of the Atlantic

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

Acute leukemias: is MRD already a surrogate for survival?

Marion Subklewe, Farhad Ravandi, Adriano Venditti

ASH 2014: Ask the experts Q&A session 1

Stephan Grupp, Catherine Bollard, Philippe Armand, Craig Moskowitz, Nicola Gökbuget

ASH 2014: Ask the experts Q&A session 2

David Steensma, Christoph Röllig, Brent Wood, Wendy Stock, Oliver Ottmann, Eytan Stein

T-cell engagers and treating relapsed ALL

Elias Jabbour, Bijal Shah, Sabina Chiaretti, Nicolas Boissel

New frontiers in ALL - MRD for clinical practice

Robin Foà, Sabina Chiaretti

ALL over the years

Dieter Hoelzer, Sabina Chiaretti

Novel treatment strategies in ALL

Robin Foà, Rob Pieters, Nicholas Short, Nicolas Boissel

Updates in ALL

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

Day 1 round up: CAR T-cell products

John Gribben, David Maloney, Noelle Frey

Immunotherapy for AML & ALL

Marion Subklewe, Richard Stone, Ivana Gojo

The future treatment of acute leukemias: part II

Andrew Wei, Mark Levis, Alan Burnett

The future treatment of acute leukemias: part I

Andrew Wei, Mark Levis, Alan Burnett

iwAL 2019: CAR-T & cellular therapies in AML and ALL

Wendy Stock, Noelle Frey, Bianca Santomasso

The evolving landscape of ALL therapy and the impact of MRD

Dieter Hoelzer, Oliver Ottmann

Biological mechanisms of AML: a 2019 update

Klaus Metzeler, Mark Levis, Ravi Majeti

Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones

Klaus Metzeler, Mark Levis, Ari Melnick, Torsten Haferlach

Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?

Klaus Metzeler, Mark Levis, Ari Melnick, Torsten Haferlach

Amyloidosis

Amyloidosis

Highlights from ASH 2024

Vaishali Sanchorawala, Ashutosh Wechalekar

Highlights from ASH 2023

Ashutosh Wechalekar, Vaishali Sanchorawala

Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored

Ashutosh Wechalekar, Vaishali Sanchorawala

Updates in diagnosis, available therapies and the multidisciplinary team

Morie Gertz, Ashutosh Wechalekar, Daniel Lenihan

Highlights from ISA 2022

Morie Gertz, Vaishali Sanchorawala, Ashutosh Wechalekar, Shaji Kumar

The role of lysosomes in amyloidogenesis by mesangial cells

Guillermo Herrera, Elba Turbat-Herrera

Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics

Faith Davies, Gareth Morgan, Keith Stewart

Novel targets in 2022

Faith Davies, Hearn Jay Cho, Charlotte Pawlyn

Post-ASH 2020

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo, Ashutosh Wechalekar

Amyloidosis: diagnosis and stem cell transplantation

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo

How will novel agents affect the amyloidosis population?

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo

Amyloidosis Sessions: Highlights from ISA 2022

Morie Gertz, Vaishali Sanchorawala

Amyloidosis Sessions: Highlights from ISA 2022

Shaji Kumar, Ashutosh Wechalekar

Amyloidosis Sessions: Highlights from ASH 2024

Ashutosh Wechalekar, Vaishali Sanchorawala

General Hematology

General Hematology

Post-ASH 2025 Highlights

Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting

Peter Voorhees, Holly Lee

Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more

Kenneth Anderson, Francesco Maura, Mehmet Samur

Immuno- and targeted therapies in high-risk myeloma: ADCs, targeting GPRC5D & more

Ajai Chari, Nisha Joseph, Ross Firestone

The value and mission of the International Workshop on Acute Leukemias

Marina Konopleva, Charles Craddock, Naval Daver

Expanding the CAR platform for NHL

Catherine Bollard, Tanya Siddiqi, Mazyar Shadman, Connor Johnson

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL

Martin Hutchings, Elizabeth Budde, Lorenzo Falchi, Sameh Gaballa

Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more

Stephen Ansell, Michael Wang, Tycel Phillips

Novel therapies and ongoing trials in NHL: advances in antibody-based combinations

Laurie Sehn, Gilles Salles, Juan Alderuccio

Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists

Paolo Strati, Evandro Bezerra, Andrew Jallouk

Immunotherapy in AML: translational insights and promising avenues being explored

Marion Subklewe, John DiPersio, Jeffrey S. Miller, Nelli Bejanyan, Ann-Kathrin Eisfeld

Is pre-transplant intervention warranted in patients with MRD-positive AML?

Eytan Stein, Maximilian Stahl

iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more

Marina Konopleva, Harry Erba, Thomas Cluzeau, Aditi Shastri

Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies

Andrew Wei, Eunice Wang, David Sallman, Gabriel Mannis

iwMDS wrap-up: translating research into practice to optimize patient care

Amer Zeidan, Andrew Brunner, Lisa Pleyer, Elizabeth Griffiths, Yasushi Miyazaki

Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity

David Steensma, Shahram Kordasti

Post-EHA & ICML 2025 Highlights

Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease

Arnon Kater, Paolo Ghia

Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics

Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy

Elizabeth Budde, Michael Jain, Marco Ruella, Mohammad Rashidian

Important considerations for community oncologists regarding the use of T-cell therapies in myeloma

Rachid Baz, Damian Green

T-cell engagers and CARs in myeloid malignancies

Marion Subklewe, Jae Park, David Sallman, Andrew Kuykendall

Integrating autoimmune diseases into cellular therapy centers

Frederick Locke, David Miklos, Lazaros Lekakis, Sarah Nikiforow

Improving access and delivery of CAR T-cells and bispecific antibodies in the community

Caron Jacobson, Krish Patel, Tara Graff

Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more

Rafael Fonseca, Ola Landgren, Thomas Martin, Adriana Rossi

Evaluating mechanisms of resistance to myeloma therapies & implications for clinical practice

Leif Bergsagel, Charlotte Pawlyn

CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations

Tycel Phillips, Krish Patel, Alexey Danilov

Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more

Yi Lin, Rakesh Popat, Sham Mailankody, Doris Hansen

Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more

Saar Gill, Francesco Maura, Maik Luu, Ciara Freeman

Clinician & patient perspectives on the value of MRD in myeloma: what should patients know?

Joseph Mikhael, Jenny Ahlstrom

Ongoing research at the MMRF: Horizon Clinical Trials Program

Hearn Jay Cho, Sham Mailankody, George Mulligan, Cindy Varga

CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more

Noelle Frey, Bijal Shah, Claire Roddie, Rebecca Gardner

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

David Maloney, Mazyar Shadman, Alexey Danilov

Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more

Paolo Strati, Manali Kamdar, Gloria Iacoboni

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment

Barbara Eichhorst, Anna Schuh, Lydia Scarfò

The value of BTK inhibitors in the treatment of frontline and relapsed MCL: expert insights

Tycel Phillips, Krish Patel, Craig Portell

A European study investigating patient-reported outcomes of CAR T-cell therapy

Anne Spanjaart, Elise Pennings

Post-ASH 2024 Highlights

Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms

Alex Rampotas, Zoë Wong

Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment & multidisciplinary care

Marlise Luskin, Shai Shimony, Nicole LeBoeuf

Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor

George Mulligan, Chaitanya Acharya

Post-ASCO & EHA 2024 Thalassemia Highlights

Post-ASCO & EHA 2024 Sickle Cell Disease Highlights

Rabi Hanna, Elisabeth Dovern, Richard Drachtman, Raffaella Colombatti, Françoise Bernaudin, Santosh Saraf, Subarna Chakravorty, Sara Trompeter

The role of BTK inhibitors in the treatment of MCL: ongoing trials and future outlooks

Tycel Phillips, Manali Kamdar

The i4MDS consortium and immune monitoring in MDS

Shahram Kordasti, Sanam Loghavi

BPDCN: treatment & management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients

Marina Konopleva, Naveen Pemmaraju, Emanuele Angelucci

The importance of cardio-oncology, awareness around the ESC 2022 guidelines & building a multidisciplinary team

Daniel Lenihan, Raúl Córdoba, Iskra Pusic

Key highlights in sickle cell disease at ASH 2023

Rabi Hanna, Josu de la Fuente

Key highlights in thalassemia at ASH 2023

Maria Domenica Cappellini, Kevin Kuo

Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more

Claire Harrison, Ruben Mesa, Jean-Jacques Kiladjian

Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored

Ashutosh Wechalekar, Vaishali Sanchorawala

Session highlights and overview: exploring the cellular origins of multiple myeloma

Leif Bergsagel, Marta Chesi

Should patients with AML receive treatment before transplantation?

Johannes Schetelig, Gesine Bug

Looking forward to the EBMT 2023 Trainee Day

Nico Gagelmann, Claire Horgan

Inhibition of RIP1 to prevent acute GvHD

James Ferrara, Mariano Prado-Acosta

Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more

David Sallman, Andrew Brunner

Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks

Kate Cwynarski, Swaminathan Iyer

Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies

Michael Dickinson, Tycel Phillips

Key highlights in MPNs: novel agents, combinations, and the potential role of immunotherapy

Aaron Gerds, Lucia Masarova

Identification of a T-cell population associated with outcomes in myeloma with t(4;14) translocation

Andreas Schmidt, Jonathan Scolnick

Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks

Yi Lin, Krina Patel

Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis

Matthew Davids, Lindsey Roeker

Upcoming trials and agents in T-cell lymphoma

Kate Cwynarski, Gloria Iacoboni

EBMT 2023 GvHD Highlights

Nico Gagelmann, Zinaida Perić

Patient-reported outcomes in CAR-T recipients

Heather Jim, Kedar Kirtane, Laura Oswald

Exploring the potential of CAR-T therapy in CLL

John Gribben, Saar Gill, Mazyar Shadman

Addressing the major challenges to CAR-T therapy in AML

John DiPersio, Saar Gill, Rizwan Romee

The future of CAR-T therapy in ALL

Noelle Frey, Bijal Shah, Shannon Maude

iwCAR-T day 2 highlights

John Gribben, Noelle Frey, David Maloney

Patient focused CAR-T updates

Kedar Kirtane, Laura Oswald, Heather Jim

Day 2 wrap-up: pushing myeloma boundaries

Rafael Fonseca, Gareth Morgan, Keith Stewart, Leif Bergsagel

T-Cell Engagers: targets, challenges and opportunity

Thomas Martin, Hermann Einsele, Nina Shah

Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics

Faith Davies, Gareth Morgan, Keith Stewart

Novel targets in 2022

Faith Davies, Hearn Jay Cho, Charlotte Pawlyn

Genomics in the age of I-O

Gareth Morgan, Francesco Maura, Leo Rasche

EBMT Trainee Committee & Young EHA Ambassadors: educating trainees about CAR-T

Nico Gagelmann, Claire Horgan

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

David Sallman, Andrew Brunner

Next steps for myeloma research and treatment

Faith Davies, Gareth Morgan

Patient segmentation for targeted therapy in myeloma

Faith Davies, Gareth Morgan

The new era of myeloma therapies

Irene Ghobrial, Maria Victoria-Mateos

Precursor conditions: management of smoldering myeloma

Irene Ghobrial, Maria Victoria-Mateos

The IMW 2021 congress and COVID-19

Heinz Ludwig, Hermann Einsele

Long-term disease-free survival in myeloma

Heinz Ludwig, Hermann Einsele

Post-EBMT for Trainees

Nico Gagelmann, Claire Horgan

Post-EBMT

Nico Gagelmann, Christian Chabannon, Zinaida Perić, Eolia Brissot

CAR-T & Nursing

John Murray, Rose Ellard, Erik Aerts, Michelle Kenyon

Post-ASH 2020

Bruce Levine, Christian Chabannon

COVID & Hematology

Amer Zeidan, John Mascarenhas, , Rory Shallis

Endotheliopathy is essential in COVID-19 associated coagulopathy

George Goshua, Alfred Ian Lee

The MAGIC algorithm probability: a novel response biomarker for acute GvHD

Hrishikesh Srinagesh, James Ferrara

Toxicity issues with CAR T-cell therapy

Noelle Frey, Bianca Santomasso, Daniel Lee

Expert discussion on CAR-T updates in lymphoma

Ian Flinn, Caron Jacobson, Stephen Schuster, Frederick Locke

What's the latest on CAR-T in ALL?

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

CLL and CAR-T

Saar Gill, Tanya Siddiqi, Jordan Gauthier

CAR T-cell therapy in myeloma

Edward Stadtmauer, Yi Lin, Krina Patel

Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

John Gribben, David Maloney, Saar Gill

Day 1 round up: CAR-T toxicity

John Gribben, David Maloney, Noelle Frey

Highlights from iwCLL 2019: MRD and novel therapies

William Wierda, Lydia Scarfò

Assessing the role of CAR-T in CLL

David Maloney, Johannes Schetelig

CLL biology and patient stratification

Barbara Eichhorst, Arnon Kater, Thomas Kipps

Amyloidosis: diagnosis and stem cell transplantation

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo

How will novel agents affect the amyloidosis population?

Morie Gertz, Vaishali Sanchorawala, Raymond Comenzo

MRD evaluation: a key component of MM management?

Mohamad Mohty, Elena Zamagni, Joaquin Martinez-Lopez

CAR-T: hurdles and ladders

Faith Davies, Noopur Raje, David Avigan, Adam Cohen

Immunotherapy in myeloma: current strategies and future perspectives

Niels van de Donk, Saad Usmani, Ajai Chari

iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine

John Gribben, Anas Younes, Caron Jacobson

CAR T-cells in lymphoma: where are we now?

James Kochenderfer, David Maloney, William Go, Stephen Schuster

iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine

John Gribben, Stephen Ansell, Catherine Bollard

Immunotherapy for NHL: checkpoint inhibitors, considerations & the future

John Gribben, Stephen Ansell, Robert Chen

Cellular therapy and drug access for viral lymphomas

Catherine Bollard, Mark Roschewski, Ruth Jarrett, Richard Little

Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance

Keith Stewart, Thomas Martin, Florian Bassermann

Myeloma 2018 day 1 highlights: precision medicine, epigenetics & novel targets

Keith Stewart, Sagar Lonial, Kenneth Anderson

CAR T-cells in myeloma: exploratory targets & payment models

Andrew Spencer, Ravi Vij, David Siegel

Where in the treatment sequence should CAR T-cells be used for myeloma?

Andrew Spencer, Ravi Vij, David Siegel

Global initiative: the EBMT Nurses Group collaborative project in India

Aleksandra Babic, Meera Achrekar

Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

iwAL 2018: a plethora of new drugs & their impact on trial design

Wolfgang Hiddemann, Mark Levis, Richard Stone, Alan Burnett

iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL

Charles Mullighan, Daniel DeAngelo, Richard Larson

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

John DiPersio, Naval Daver, Richard Stone, Noelle Frey

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Gareth Morgan, Keith Stewart, Leif Bergsagel

The use of CAR T-cells in multiple myeloma

Yi Lin, Adam Cohen, Sabrina Prommersberger

The future of immunotherapy in multiple myeloma

Hearn Jay Cho, Tuna Mutis, Ivan Borrello

Exciting new developments in multiple myeloma

Irene Ghobrial, Lawrence Boise, Daniel Auclair, Nina Shah, Jonathan Keats

How immunotherapies are re-shaping the treatment of lymphoma

Stephen Ansell, Catherine Bollard, Steve Gottschalk

COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards

Mohamad Mohty, Arnon Nagler

iwNHL 2016: Highlights from Day 1

John Gribben, Catherine Bollard, Wyndham Wilson, Laurence de Leval

Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cure

Nathan Fowler, Anas Younes, James Kochenderfer, David Maloney

Panel discussion on T-cell lymphoma: current status of therapy and progress

John Gribben, Laurence de Leval, Francine Foss, Elaine Jaffe

An update on immunotherapy for multiple myeloma in 2016

Jesús San Miguel, Paula Rodríguez-Otero, Ignacio Bermejo

EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?

Pierre Fenaux, Joan Lluis Vives-Corrons

An overview of the European Reference Networks and EuroBloodNet

Pierre Fenaux, Joan Lluis Vives-Corrons

The role of patients and patient groups in the European Reference Network EuroBloodNet

Pierre Fenaux, Joan Lluis Vives-Corrons

Myeloma 2016: Panel discussion on gene modified T-cells

James Kochenderfer, Edward Stadtmauer, Michael Hudecek, Ivan Borrello

MMRF presents highlights for patients at Myeloma 2016

Keith Stewart, Sagar Lonial, Daniel Auclair, Kenneth Anderson

Myeloma 2016: Panel discussion on novel treatments

Keith Stewart, Sagar Lonial, Leif Bergsagel, Kenneth Anderson

Rapid CAR manufacture

Caron Jacobson, Valentín Ortiz-Maldonado, Matthew Frigault

Current challenges in CAR-T

Marco Davila, Evan Weber, Filip Ionescu, Michael Green

Prophylaxis and management of CRS & ICANS

Bianca Santomasso, Matthew Frigault

The need for academic and pharmaceutical collaboration in drug development

John Gribben, Jay Bradner

Triple combination therapies for multiple myeloma (MM) patients

Heinz Ludwig, Niels van de Donk

Results of the Phase II TITAN study of caplacizumab in patients with aTTP

Flora Peyvandi, Spero Cataland, Marie Scully

Myeloma 2016: Panel discussion on the new treatment paradigm

Gareth Morgan, Jesús San Miguel, Keith Stewart, Kenneth Anderson

Novel lymphoma targets and agents

Andrew Zelenetz, Laurie Sehn

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs

James Kochenderfer, Adam Cohen, Andrzej Jakubowiak

The definitive guide to multiple myeloma at ASH 2018: part IV

Mohamad Mohty, Saad Usmani

The evolving landscape of ALL therapy and the impact of MRD

Dieter Hoelzer, Oliver Ottmann

AML treatment: what does the data say?

Christoph Röllig, Adriano Venditti, Richard Larson

iwAL 2019: CAR-T & cellular therapies in AML and ALL

Wendy Stock, Noelle Frey, Bianca Santomasso

Novel approaches and targeted therapies in 2019 for AML

Andrew Wei, Mark Levis, Torsten Haferlach

The future treatment of acute leukemias: part I

Andrew Wei, Mark Levis, Alan Burnett

The future treatment of acute leukemias: part II

Andrew Wei, Mark Levis, Alan Burnett

Immunotherapy for AML & ALL

Marion Subklewe, Richard Stone, Ivana Gojo

CAR-T vs bispecific antibodies for lymphoma

John Gribben, David Maloney, Laurie Sehn

Highlights from IMW 2019 Part I

Katja Weisel, Francesca Gay

Day 1 round up: CAR T-cell products

John Gribben, David Maloney, Noelle Frey

Inflammation, immune dysregulation and targeting in MDS

Alan List, David Sallman, Uwe Platzbecker, Daniel Starczynowski

Updates in AML

Marion Subklewe, David Sallman, Roman Shapiro

Lymphoma CAR and bispecific updates

Loretta Nastoupil, Tycel Phillips, Mazyar Shadman

Updates in ALL

Bijal Shah, Claire Roddie, Nirav Niranjan Shah, Rebecca Gardner

Updates in CLL

John Gribben, Tanya Siddiqi, Joseph Melenhorst

Updates in multiple myeloma

Rafael Fonseca, Yi Lin, Nizar Bahlis, Sham Mailankody

Resistance mechanisms mediated by the microenvironment in multiple myeloma

Irene Ghobrial, Lawrence Boise, Charlotte Pawlyn, Paola Neri

Using animal models & the microenvironment to better understand the biology of multiple myeloma

Bruno Paiva, Maria Victoria-Mateos, Marta Chesi, Jose Martinez-Climent

The future of myeloma therapy

Brian Walker, Keith Stewart, Martin Kortüm, Claudia Stege

Novel therapeutic strategies in multiple myeloma

Enrique Ocio, Carlos Fernández De Larrea, Elena Zamagni, Nizar Bahlis

Reaching a cure for multiple myeloma

Gareth Morgan, Sagar Lonial, Pieter Sonneveld

Key myeloma highlights from EHA 2023

Jesús San Miguel, Enrique Ocio

Updates in CAR-T and bispecific antibodies for LBCL from EHA 2023

Paolo Strati, Gloria Iacoboni

Transplantation & immunotherapies

Charles Craddock, Mark Levis, David Sallman, Nelli Bejanyan

New therapeutic targets in DLBCL

Ash Alizadeh, Laura Pasqualucci, Ken Young

Expanding the CAR platform in NHL

David Maloney, David Miklos, Jason Westin

Bispecific antibodies in NHL

Marion Subklewe, Martin Hutchings, Mazyar Shadman, Krish Patel

Novel therapies in NHL: antibody-drug conjugates

Andrew Davies, John Gribben, Laurie Sehn, Sven De Vos

Early interception in SMM & novel agents being explored

Irene Ghobrial, Kwee Yong, Omar Nadeem

The value of genomics in multiple myeloma & applying this in clinical practice

Gareth Morgan, Arun Wiita, Francesco Maura, Sarah Gooding

Understanding mechanisms of resistance to targeted therapies in myeloma

Leif Bergsagel, Charlotte Pawlyn, Paola Neri, Francesco Maura

Clinical trial updates in myeloma: managing bone disease, the use of isatuximab, belantamab mafodotin & more

Ola Landgren, Suzanne Lentzsch, Thomas Martin, Suzanne Trudel

Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities

Faith Davies, Gareth Morgan, Louis Williams

Novel targets & agents in myeloma

Faith Davies, Mala Shanmugam, Sikander Ailawadhi

History and upcoming projects of the MMRF

Lawrence Boise, Hearn Jay Cho

An update on CAR-T in CLL

Saar Gill, Tanya Siddiqi

CAR T-cells for autoimmune diseases

The future of CAR-T therapy in AML

David Sallman, Fabiana Perna

New directions and governmental progress in MDS: insights into MyeloMATCH & CTEP

Olatoyosi Odenike, Maximilian Stahl, Elizabeth Griffiths, Steven Gore

Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more

Andrew Wei, Amer Zeidan, Uwe Platzbecker, Aditi Shastri

Unmet needs in MF and focusing on early intervention in patients with MPNs

Claire Harrison, Naveen Pemmaraju, Aaron Gerds, Abdulraheem Yacoub

Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease

Marina Konopleva, Richard Stone, Thomas Cluzeau

Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs

Andrew Wei, Farhad Ravandi, David Sallman, Sanam Loghavi

Bispecific antibodies in NHL: comparisons with CAR-T, managing toxicities, & combination approaches

Marion Subklewe, Stephen Ansell, Martin Hutchings, Krish Patel

CAR T-cell therapy in NHL: selecting between agents, managing toxicities, & the potential of allogeneic products

Catherine Bollard, Stephen Schuster, Jason Westin

Updates in T-cell leukemia/lymphoma

Francine Foss, Lucy Cook, Kate Cwynarski, Thierry Lamy

ADCs in B-cell lymphomas: emerging data and novel targets

Laurie Sehn, Paolo Caimi, Alex Herrera, Juan Alderuccio

Evolving frontline treatment in MCL: disease biology, the changing role of SCT & novel agents

John Kuruvilla, Michael Wang, Caron Jacobson

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

Marina Konopleva, Anand Patel, Guillermo Montalban-Bravo, Emma Groarke

Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies

Niels van de Donk, Thomas Martin, Saad Usmani, Ajai Chari

CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs

Ajai Chari, Krina Patel

Defining high-risk multiple myeloma: recent advances in the field & future considerations

Kenneth Anderson, Francesco Maura, Simon Harrison

An insight into designing randomized studies in high-risk myeloma

Francesca Gay, Sham Mailankody, Binod Dhakal

Evolving treatment landscape of MCL

Stephen Ansell, Marek Trněný, John Kuruvilla, Yucai Wang

Novel targets, treatments, and combinations in AML

Richard Stone, David Sallman, Thomas Cluzeau

What do we know about drug resistance in AML?

Naval Daver, Alexander Perl, Paresh Vyas, Carsten Müller‐Tidow

Immunotherapeutics in AML

Marion Subklewe, Saar Gill, Amer Zeidan

Novel treatment strategies in ALL

Robin Foà, Rob Pieters, Nicholas Short, Nicolas Boissel

ALL over the years

Dieter Hoelzer, Sabina Chiaretti

T-cell engagers and treating relapsed ALL

Elias Jabbour, Bijal Shah, Sabina Chiaretti, Nicolas Boissel

New frontiers in ALL - MRD for clinical practice

Robin Foà, Sabina Chiaretti

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population

Heinz Ludwig, Meral Beksac

Management of high-risk and frail patients, MRD & teclistamab

Rakesh Popat, Charlotte Pawlyn

The role of super-enhancers in multiple myeloma & mechanisms of resistance to IMiDs and T cell-directed therapies

Leif Bergsagel, Marta Chesi

Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies

Mohamad Mohty, Saad Usmani

Myeloma treatment updates: a UK perspective

Martin Kaiser, Graham Jackson

CLL updates from SOHO 2022: novel treatment strategies, the promise of next-generation BTK inhibitors & more

Nitin Jain, Catherine Coombs

Improving transplant outcomes in AML

Charles Craddock, Christopher Hourigan

Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS

Valeria Santini, Amer Zeidan

Amyloidosis Sessions: Highlights from ISA 2022

Morie Gertz, Vaishali Sanchorawala

Amyloidosis Sessions: Highlights from ISA 2022

Shaji Kumar, Ashutosh Wechalekar

Amyloidosis Sessions: Highlights from ASH 2024

Ashutosh Wechalekar, Vaishali Sanchorawala

Lymphoma Sessions: CAR-T and lymphoma treatment in the UK

Robin Sanderson, Tobias Menne